SLU-PP-332: Side Effects & Safety
Part of the SLU-PP-332 Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Overall Safety Profile
SLU-PP-332 is preclinical only — no human safety data exists. Animal studies did not report significant toxicity over the study durations, but comprehensive safety evaluation has not been performed.
Observed Effects in Animals
- No significant toxicity reported in published mouse studies
- Body weight changes: Reduced weight gain on high-fat diet (therapeutic effect)
- No behavioral abnormalities observed during study periods
Critical Safety Limitations
ERR activation affects multiple organ systems beyond skeletal muscle — cardiac, hepatic, and reproductive effects would need thorough evaluation before human use. ERR signaling plays context-dependent roles in certain cancers, requiring careful safety assessment. No pharmacokinetic, pharmacodynamic, or toxicology studies in humans have been conducted.
Theoretical Contraindications
- Active cancer (ERR signaling role in tumor biology)
- Cardiac conditions (ERR affects cardiac metabolism)
- Pregnancy and breastfeeding
- No drug interaction data available